Skip to content
Study details
Enrolling now

Repurposing Low-Dose Clonidine for PTSD in Veterans

Wake Forest University Health Sciences
NCT IDNCT04877093ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

32

Study length

about 2.8 years

Ages

18+

Locations

1 site in WI

About this study

This trial is testing whether low-dose clonidine helps veterans with PTSD. It compares clonidine to a placebo pill over 1034 days. The goal is to see if the treatment improves PTSD symptoms, including daytime and nighttime issues.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Take Clonidine Pill
PhasePhase 3
DrugClonidine Pill
Routeoral
Primary goalChange from Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) questions B2 and E6 at 6 weeks into phase

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

CARDIOVASCULAR SYSTEM

Drug routes

oral

Endpoints

Primary: Change from Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) questions B2 and E6 at 6 weeks into phase, Change from Baseline in PTSD Checklist-Military Version (PCL-5) at 6 weeks into phase, Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) at 6 weeks into phase

Secondary: Change from Baseline in Patient Health Questionnaire (PHQ9) at 6 weeks into phase, Change from Baseline in Sleep Diary at 6 weeks into phase, Change from Baseline in quality of life scale (Q-LES-Q-SF) at 6 weeks into phase

Body systems

Psychiatry / Mental Health